A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TNX-1500 in Healthy Subjects

Exclusion Criteria

• •1. history of an anaphylactic reaction to parenteral administration of contrast agents, human or murine proteins, mAbs, or allergy to any of the TNX-1500 components
• •2. history of shellfish allergy
• •3. increased risk for thromboembolic events due to an ongoing heart disease or due to a medical device, including but not limited to vascular graft, valvular heart disease, atrial fibrillation, or a heart rhythm disorder
• •4. use of any hormonal replacement therapy or oral, transdermal, IUD, or injectable hormonal contraception
• •5. history of confirmed venous thromboembolism, arterial thrombosis, coagulopathy, or known platelet disorders
• •6. history of diabetes, clinically significant and currently relevant cardiovascular, pulmonary, hepatic, or kidney diseases, as determined by the Investigator
• •7. history of protein C or protein S deficiency disorders and/or clinically significant abnormality in protein C and protein S levels at Screening
• •8. requiring treatment with antiplatelet and/or antithrombotic drugs
• •9. received any doses of Janssen/Johnson \& Johnson COVID-19 vaccine
• •10. history of major surgery in the last 6 months or plans to undergo elective surgery during the study period
• •11. clinically significant abnormality upon physical examination at Screening, as determined by the Investigator
• •12. use of tobacco, smoking cessation products, or products containing nicotine within 3 months prior to Screening
• •13. history of alcohol or illicit drug use disorder, marijuana use disorder as defined in the Diagnostic and Statistical Manual of Mental Disorders, 5th edition, or a reported habitual alcohol intake greater than 1.5 oz (ethanol equivalent) per day (eg, 24 oz of beer, 10 oz of wine, or 3 oz of hard liquor) for the past two years
• •14. positive urine screen for drugs of abuse including but not limited to tetrahydrocannabinol, or elevated ethanol breathalyzer concentration on admission to the study center at Screening or at Check-in (Day -1)
• •15. positive serologic test for hepatitis B surface antigen, hepatitis B core antibody, hepatitis C virus antibody, human immunodeficiency virus
• •16. negative for EBV viral capsid antigen IgG, Epstein-Barr nuclear antigen IgG
• •17. history of positive tuberculin (TB) test or positive QuantiFERON® TB Gold at Screening
• •18. clinically significant abnormality on 12-lead ECG at Screening, as determined by the Investigator
• •19. clinically significant abnormal laboratory values (clinical chemistry, hematology, coagulation, or urinalysis) outside the reference values established by the laboratory, as determined by the Investigator at Screening or at Check-in (Day -1)
• •20. positive pregnancy test for women of childbearing potential (WOCBP) or lactating at Screening or at Check-in (Day -1)
• •21. participation in an investigational study within 30 days or within 5 half-lives of the investigational drug, whichever is longer, prior to the Screening Visit
• •22. receiving any antibody or biologic medicinal product within 90 days prior to Screening
• •23. unable to refrain from or anticipates the use of any prescription and/or non-prescription medications, vitamins, herbal, or dietary supplements beginning 14 days prior to the first dose of study medication and throughout the study, with the exception of occasional 'as-needed' use of acetaminophen at a dose of ≤1000 mg/day
• •24. COVID-19 infection within 28 days prior to Check-in (Day -1) and/or a positive test for severe acute respiratory syndrome coronavirus 2 antigen testing or equivalent testing at Check-in (Day -1)
• •25. previous exposure to KLH
• •26. history of vaccination (with the exception of COVID-19 vaccination) within 60 days prior to the Screening, or anticipated need for any type of vaccination(s) and/or boosters (including COVID-19 booster) throughout the study
• •27. history or presence, upon clinical evaluation, of any illness that, in the opinion of the Investigator, would interfere with the ability to provide informed consent or comply with study instructions, or that might confound the interpretation of the study results or put the subject at undue risk.
• •28. abnormal renal function (FDA, 2020) (Appendix 2) based on an estimated glomerular filtration rate (eGFR; CKD-EPI 2021 equation) (National Kidney Foundation, 2021) \< 60 mL/min at screening or at Check-in (Day -1).
• •29. moderate to severe hepatic impairment as per the Child-Pugh system (FDA, 2003) (Appendix 3). Exclude if Child-Pugh system score is \> 6 points based on: encephalopathy grade; level of ascites; serum bilirubin, mg/dL; serum albumin, g/dL; and prothrombin time, sec prolonged. Note: elevated bilirubin due to Gilbert's syndrome is not exclusionary.